Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.

Literature DB >> 17913723

Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.

Eva Poveda, Carolina Garrido, Carmen de Mendoza, Angélica Corral, Julio Cobo, Juan González-Lahoz, Vincent Soriano.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17913723 DOI： 10.1093/jac/dkm372

Source DB: PubMed Journal: J Antimicrob Chemother ISSN： 0305-7453 Impact factor: 5.790

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.

Authors: Eugene L Asahchop; Mark A Wainberg; Richard D Sloan; Cécile L Tremblay
Journal: Antimicrob Agents Chemother Date: 2012-06-25 Impact factor: 5.191

Review 2. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors: Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal: World J Virol Date: 2015-05-12

3. Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults.

Authors: Marianne Harris; Jonathan B Angel; Jean-Guy Baril; Anita Rachlis; Benoit Trottier
Journal: Can J Infect Dis Med Microbiol Date: 2009 Impact factor: 2.471

4. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.

Authors: Adele L McCormick; Chris M Parry; Anne Crombe; Ruth L Goodall; Ravindra K Gupta; Pontiano Kaleebu; Cissy Kityo; Michael Chirara; Greg J Towers; Deenan Pillay
Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191

5. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Authors: Anne-Genevieve Marcelin; Philippe Flandre; Diane Descamps; Laurence Morand-Joubert; Charlotte Charpentier; Jacques Izopet; Mary-Anne Trabaud; Henia Saoudin; Constance Delaugerre; Catherine Tamalet; Jacqueline Cottalorda; Magali Bouvier-Alias; Dominique Bettinger; Georges Dos Santos; Annick Ruffault; Chakib Alloui; Cecile Henquell; Sylvie Rogez; Francis Barin; Anne Signori-Schmuck; Sophie Vallet; Bernard Masquelier; Vincent Calvez
Journal: Antimicrob Agents Chemother Date: 2009-11-09 Impact factor: 5.191

6. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

Authors: Elizabeth C Reuman; Soo-Yon Rhee; Susan P Holmes; Robert W Shafer
Journal: J Antimicrob Chemother Date: 2010-05-12 Impact factor: 5.790

10. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.

Authors: Steven J Reynolds; Cissy Kityo; Frank Mbamanya; Robin Dewar; Francis Ssali; Thomas C Quinn; Peter Mugyenyi; Mark Dybul
Journal: Antivir Ther Date: 2009